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ABSTRACT
In this study, we validated the analytical performance of BRCA1/2 sequencing 
using Ion Torrent’s new bench-top sequencer with amplicon panel with optimized 
bioinformatics pipelines. Using 43 samples that were previously validated by Illumina’s 
MiSeq platform and/or by Sanger sequencing/multiplex ligation-dependent probe 
amplification, we amplified the target with the Oncomine™ BRCA Research Assay and 
sequenced on Ion Torrent S5 XL (Thermo Fisher Scientific, Waltham, MA, USA). We 
compared two bioinformatics pipelines for optimal processing of S5 XL sequence data: 
the Torrent Suite with a plug-in Torrent Variant Caller (Thermo Fisher Scientific), and 
commercial NextGENe software (Softgenetics, State College, PA, USA). All expected 
681 single nucleotide variants, 15 small indels, and three copy number variants were 
correctly called, except one common variant adjacent to a rare variant on the primer-
binding site. The sensitivity, specificity, false positive rate, and accuracy for detection 
of single nucleotide variant and small indels of S5 XL sequencing were 99.85%, 
100%, 0%, and 99.99% for the Torrent Variant Caller and 99.85%, 99.99%, 0.14%, 
and 99.99% for NextGENe, respectively. The reproducibility of variant calling was 
100%, and the precision of variant frequency also showed good performance with 
coefficients of variation between 0.32 and 5.29%. We obtained highly accurate data 
through uniform and sufficient coverage depth over all target regions and through 
optimization of the bioinformatics pipeline. We confirmed that our platform is accurate 
and practical for diagnostic BRCA1/2 testing in a clinical laboratory.
INTRODUCTION
The development of massive-parallel sequencing 
technology has facilitated the rapid and cost-effective 
generation of sequence data. Owing to the large size of the 
target region of BRCA1/2 genes and no-mutation hot spots, 
many clinical laboratories are shifting from conventional 
routine techniques to high-throughput next-generation 
sequencing (NGS) for BRCA1/2 testing [1, 2]. However, 
diagnostic genetic testing in the clinical laboratory 
requires high accuracy and an acceptable turn-around time 
for clinical decisions. Therefore, each clinical laboratory 
should put in place an appropriate NGS process including 
the wet procedure and bioinformatics analysis that meets 
the quality standards of clinical genetic testing [3–5].
Bench-top NGS sequencers optimized for targeted 
sequencing have usually been evaluated for diagnostic 
BRCA1/2 testing [1, 6–9]. The latest Ion Torrent 
sequencers, models S5 and S5 XL (Thermo Fisher 
Scientific, Waltham, MA, USA), were released in 2015. 
S5 and S5 XL require much less time for sequencing than 
previous Ion Torrent Personal Genome Machine (PGM) 
sequencer (Run time yielding 0.6–1 Gb; 2.5 hr for S5 and 
S5 XL vs. 4.4 hr for PGM) [10, 11]. Therefore, we can 
also expect an improvement in turn-around time required 
for clinical genetic testing.
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Several attempts have been made to compare the 
Illumina and Ion Torrent platforms, which adopt two 
different principles for library preparation and sequence 
generation [6, 12, 13]. The Ion Torrent platform, which 
uses semiconductor sequencing technology, has a 
reputation for higher insertion/deletion (indel) error 
rates associated with the homopolymer region than 
the Illumina platform, which sequences by synthesis 
technology [12]. However, a number of approaches 
including optimization of the bioinformatics pipeline, 
and enhancement of coverage depth and uniformity, have 
been attempted to overcome the shortcomings of the Ion 
Torrent platform [1, 9].
The aim of the current study was to validate 
and optimize the Ion Torrent S5 XL platform using the 
Oncomine™ BRCA Research Assay (Thermo Fisher 
Scientific) for routine diagnostic BRCA1/2 testing in a 
clinical laboratory. Furthermore, we used previously 
validated samples from hereditary breast and ovarian 
cancer syndrome (HBOC) patients for comparison of its 
performance with the other most commonly used platform: 
MiSeq sequencer with the TruSeq custom amplicon panel 
(both Illumina, San Diego, CA, USA) [14]. We also 
compared two variant calling methods (Torrent Variant 
Caller v5.2.0.34 vs NextGENe v2.4.1.2) for optimal 
processing of data from the Ion Torrent S5 XL.
RESULTS
S5 XL sequencing run metrics
The sequencing run metrics showed acceptable 
quality in all four batches (Table 1). The percentage of 
on-target reads, in which the ratio of the number of reads 
mapped on a target BRCA1/2 region to the total number 
of reads, was over 95%. The uniformity of base coverage 
was over 97% in all batches, and base coverage was over 
20 × at all target regions. The sequencing reads covered 
the region of interest (ROI) evenly (Figure 1).
Accuracy performance of S5 XL sequencing 
All single nucleotide variants (SNV), small indels, 
and copy number variants (CNV) were successfully 
identified, except one SNV with the same false-negative 
result from the MiSeq platform (variant profile of the 
43 samples used for NGS validation are provided in 
the online version of Supplementary Table 1) [14]. The 
analytical performance of S5 XL sequencing for SNV and 
indel calling is summarized in Table 2. Using NextGENe 
analysis, we discovered one false-positive call (BRCA2 
NM_000059.3: c.8953+15_8953+16insT) in a patient. The 
error was confirmed as a strand bias with low balance ratio 
of 0.169. The sensitivity, specificity, false positive rate, and 
accuracy for SNV and indel calling were 99.85%, 100%, 
0%, and 99.99% for Torrent Variant Caller and 99.85%, 
99.99%, 0.14%, and 99.99% for NextGENe, respectively. 
Our NGS platform also detected CNVs from three patients 
(Figure 2). According to NextGENe analysis, the deleted 
exon boundaries of each patient were all in agreement with 
MLPA results. 
One missing SNV (c.2971A>G, p.Asn991Asp in 
a patient, dbSNP ID; rs1799944) was not identified by 
Oncomine panel on S5 XL or by TruSeq custom panel 
on MiSeq [14]. After lowering the variant frequency 
cut-off to ≥ 10%, bioinformatics analysis revealed that 
the missed SNV was called with a variant frequency of 
12.7% by Torrent Variant Caller and 12.4% by NextGENe. 
In the same batch, the rs1799944 variant was correctly 
called with 46.9–50.2% variant frequency in four other 
patients. The missed SNV was covered by two primer 
sets from the Oncomine panel and one primer was located 
in the rare individual SNV of one patient (c.3011G>A, 
p.Ser1044Asn) (Figure 3A). We repeated the deep-
sequencing of the sample using the other probe set to 
confirm the allele drop-out phenomenon as the source 
of error. The missed SNV was then identified with an 
allele coverage of 4,000 × and a variant frequency of 
45%. We confirmed that the missed SNV existed in a cis-
configuration adjacent to the rare SNV (Figure 3B).
Precision performance of Ion Torrent S5 XL 
sequencing for SNV and small indel variant 
detection
To confirm the reproducibility of variant calling, the 
indel variant and SNV calling results from split samples 
are summarized in Table 3. Three indel variants and 43 
SNVs were correctly called within and between runs; 
therefore the calling reproducibility was 100%. Precision 
performance was assessed by the coefficient of variation 
(CV) of the variant frequency using true heterozygote 
variants from three patients (Table 4). The results showed 
good precision performance, with the CV between 0.32 
and 5.29% for indels, and between 3.0 and 3.86% for 
SNVs.
DISCUSSION
Here, we validated and optimized the Oncomine™ 
BRCA Research Assay and Ion Torrent S5 XL platform 
for routine BRCA1/2 testing in a clinical laboratory. 
The previously noted shortcoming of the Ion Torrent 
platform is a higher error rate over the homopolymer 
region than in the Illumina platform [12]. Previous 
literature showed a significant increase in erroneous 
indel calls in homopolymer stretch of even 3–4 bp length 
[12]. Furthermore, a previous study with Miseq revealed 
homopolymer region-associated false positives in all 
tested samples with mean variant frequency of 21.6% 
[14]. However, in this validation study, we detected no 
homopolymer region-associated false positives at variant 
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frequency cut-off of ≥ 20%. In ROI of this study, there 
was a total of 398 homopolymer regions (4–10 nucleotide 
length), which accounted for 10.1% of all target regions 
(1,797/177,21 bp, information on homopolymer stretches 
of ROI in this study are provided in the online version 
of Supplementary Table 2). A total of 66 true positive 
SNVs located in homopolymer region (47 heterozygote 
SNVs and 19 homozygote SNVs, 9.5% of total true 
positive variants) were all correctly called by our method. 
Our platform is considered suitable for analysis of genes 
with only relatively short homopolymer regions, such as 
BRCA1/2. Further validation is needed for homopolymer 
regions longer than 11 bp.
The implemented bioinformatics pipeline, Torrent 
Suite software with Torrent Variant Caller, was easy 
to use and showed optimal performance. Time and 
labor requirements for the entire process, including wet 
procedures and bioinformatics analysis, were reduced in 
our laboratory (comparison of wet-procedure time required 
for Sanger sequencing and next-generation sequencing is 
provided in the online version of Supplementary Figure 1). 
Furthermore, our platform concurrently detected CNVs, 
SNVs, and small indels. Since conventional Sanger 
sequencing cannot detect large deletion/duplication, a 
parallel copy number analysis testing, such as MLPA, is 
required. Our approach offers the benefit of reduced time 
and effort for CNV analysis.
A possible limitation of our study is that we only 
included small-sized indels, which were ≤ 11 bp. There 
were 7,965 reported variants in BRCA1 and 9,816 variants 
in BRCA2, according to the dbSNP database (https://
www.ncbi.nlm.nih.gov/SNP/). Among them, the number 
of variants with sizes that are not included in this study 
(11–400 bp) was 15 for BRCA1 (0.41%) and 26 for 
BRCA2 (0.15%), respectively. Although the proportion 
of large pathogenic indels in BRCA1/2 is relatively low, 
further validation is required using indels that are larger 
than 11 bp.
A false-negative variant in this study was caused 
by the allele drop-out phenomenon from a rare variant at 
the primer-binding site. The allele drop-out phenomenon 
is known to be an error source in all polymerase chain 
Table 1: S5 XL sequencing run statistics
Batch 1 Batch 2 Batch 3 Batch 4
On-target reads, % 95.85 95.48 95.65 95.29
On-target base reads, % 93.79 93.27 93.47 92.9
Uniformity of base coverage at 0.2, % 97.69 99.97 99.98 99.63
Average depth per sample (min, max)
1957 × (1062 ×, 
3625 ×)
2056 × (1272 ×, 
2780×)




Average depth of on-target regions 
(min, max)
1834 × (997 ×, 
3389 ×)
1834 × (997 ×, 
3389 ×)




Target bases with no strand bias, % 98.08 98.76 98.41 98.53
Target base coverage at 20×, % 100 100 100 100






















































GATK = genome analysis toolkit; CI = confidence interval.
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reaction (PCR)-based techniques [15, 16]. If the rare and 
target variants exist in the trans-configuration, the target 
variant can be detected, even if one allele is dropped 
during PCR amplification. However, in our case, the 
rare and missed variants existed in the cis-configuration; 
the missed variant was detected only in other amplicons 
and accounted for only part of the total reads. When the 
variant frequency cut-off was decreased from 20% to 10%, 
a missing variant was called. However, false positive rate 
increased from 0.14% (one false-positive call) to 6.82% 
(51 false-positive calls). Therefore, we chose a variant 
frequency cutoff of 20%, and checked for missing true-
positive calls in cases of samples with no pathogenic 
variant.
In conclusion, the Oncomine™ BRCA Research 
Assay used with the Ion Torrent S5 XL platform showed 
acceptable analytical sensitivity, specificity, accuracy, and 
precision performance for the detection of SNVs, small 
indels, and CNVs. The bioinformatics pipeline using Torrent 
Suite software with Torrent Variant Caller was optimized for 
the analysis of S5 XL data. In analysis of BRCA1/2 genes, 
we confirmed that the error associated with homopolymer 
Figure 1: Coverage plots from (A) 40 patients without copy number variant and (B) three representative samples showed 
uniform coverage across the entire region of interest. Y-axis indicates sequence read depth and x-axis indicates target 
Oncotarget34862www.impactjournals.com/oncotarget
region is not a major problem in this new Ion Torrent 
assay. Further validation study is needed to evaluate the 
performance for longer homopolymer regions. It is important 
to note that a rare individual variant can be a source of error 
because it causes the allele drop-out phenomenon in deep 
sequencing, as with other PCR-based methods. NGS is a 
reliable and practical tool for clinical BRCA1/2 testing.
MATERIALS AND METHODS
Patients and DNA samples
We included 40 Korean HBOC patients who had 
previously been subjected to Sanger sequencing and 
Illumina’s MiSeq platform for BRCA1/2 genetic variants 
[14]. Among the cohort samples, difficult cases with false 
negative or false positive calls from MiSeq were selected 
for this study. Ultimately, we included 12 samples with 
pathogenic variant, 11 samples with variants of unknown 
significance, and 17 samples with likely benign/benign 
variants. Since the 40 samples only had SNVs and small 
indels that were either smaller than or equal to 11 bp, we 
added three more samples with BRCA1 pathogenic CNV 
that had been confirmed by multiplex ligation-dependent 
probe amplification (MLPA) to evaluate the performance 
of CNV detection. This study was approved by the hospital 
institutional review board, and informed consent was 
obtained from each patient. Genomic DNA was extracted 
from whole blood using a QIAamp DNA Blood Mini Kit 
(Qiagen, Venlo, The Netherlands). Each DNA sample was 
checked for purity using a NanoDrop 1000 system (Thermo 
Fisher Scientific) and for concentration using a Qubit 3.0 
Fluorometer (Thermo Fisher Scientific). The concentration 
of input DNA was then adjusted to 0.67 ng/μL. The MLPA 
was performed using P002-D1 BRCA1 and P045 BRCA2/
CHEK2 probemixes (MRC-Holland, Amsterdam, The 
Netherlands) according to the manufacturer’s instructions. 
The MLPA result was analyzed using GeneMarker software 
(Softgenetics, State College, PA, USA).
Library preparation and Ion S5 XL sequencing
Overall library preparation was carried out using 
an Ion Chef System (Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Briefly, barcoded 
libraries were generated from 10 ng of DNA per sample 
Figure 2: Copy number analysis plots from NextGENe software. Our platform successfully detected three CNVs. (A) Exon 12-
14 deletion, (B) exon 4-7 deletion, and (C) exon 8-23 deletion in BRCA1.
Oncotarget34863www.impactjournals.com/oncotarget
Figure 3: A false-negative variant from a previous study [14] using the MiSeq platform and S5 XL sequencing. (A) A 
common single nucleotide variant (SNV) in BRCA2 (c.2971A>G, p.Asn991Asp; red solid bordered box) showed low variant frequency 
(12.7%) according to S5 XL sequencing owing to a rare SNV (c.3011G>A, p.Ser1044Asn; red dotted bordered box) on the primer-binding 
site. (B) Deep-sequencing using the other probe set revealed that the missed SNV and the adjacent rare SNV were in a cis-configuration.
Table 3: Reproducibility of indel variants and single nucleotide variant (SNV) detection





















1 1 3 1 1 3 1 1 3 100
YMC2: BRCA2, 
c.2798_2799del
1 1 3 1 1 3 1 1 3 100
YMC3: BRCA1, 
c.922_924delinsT
1 1 3 1 1 3 1 1 3 100
YMC1: 12 SNVs 1 1 3 12 12 36 12 12 36 100
YMC2: 13 SNVs 1 1 3 13 13 39 13 13 39 100
YMC3: 18 SNVs 1 1 3 18 18 54 18 18 54 100
SNV = single nucleotide variant; YMC = Yonsei Medical Center.
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using an Ion AmpliSeq Chef Solutions DL8 Kit (Thermo 
Fisher Scientific) and an Oncomine™ BRCA Research 
Assay (Thermo Fisher Scientific). Two premixed pools 
of 265 primer pairs were used to generate the sequencing 
libraries. Clonal amplification of the libraries was carried 
out by emulsion PCR using an Ion AmpliSeq IC 200 Kit 
(Thermo Fisher Scientific). The prepared libraries were 
then sequenced on an Ion S5 XL Sequencer using an Ion 
520 Chip and an Ion 520 kit–Chef Kit (all Thermo Fisher 
Scientific). Fifty-two tests were conducted in four separate 
batches by two different technologists working in shifts 
(only three samples with CNV were tested in another 
batch). Split samples from three patients with indel variants, 
which represent important and difficult case, were used to 
assess between-run and within-run precision performance. 
DNA samples were divided into aliquots and assayed (once 
in the first and second batches, and with three replicates in 
the third batch) to evaluate precision performance.
Bioinformatics analysis
Generated raw sequence data in FASTQ format were 
aligned to the hg19 human reference genome using the 
Torrent Mapping Alignment Program aligner implemented 
in v5.2 of the Torrent Suite software (Thermo Fisher 
Scientific). For SNV calling, we used two software 
programs in parallel—plug-in Torrent Variant Caller 
v5.2.0.34 (Thermo Fisher Scientific) and commercial 
NextGENe v2.4.1.2 (Softgenetics)—to generate a variant 
call format file. For Torrent Variant Caller analysis, default 
setting of germline low-stringency parameters (minimal 
variant frequency of 0.1, minimum variant quality of 10, 
minimum coverage of 5 ×, maximum strand bias of 0.98, 
and minimum variant score of 10) was used and candidate 
variants were obtained only when variant frequency at a 
given position of ≥ 20% and variant coverage of ≥ 20×. For 
NextGENe analysis, candidate variant was called using the 
following setting parameters: minimum variant frequency 
of 0.1; minimum SNV balance ratio (number of forward 
reads/ number of reverse reads) of 0.1; and minimum 
homopolymer indel balance ratio of 0.8. Candidate 
variants were obtained after filtering variant of low 
coverage (< 20×). For equivocal variant calls from Torrent 
Variant Caller and NextGENe, Integrative Genomics 
Viewer v2.3 software (Broad Institute, Cambridge, MA, 
USA) and NextGENe Viewer (SoftGenetics) were used to 
visualize the sequence reads and alignments and identify 
sequencing errors, respectively.
CNV analysis was performed with dispersion and 
Hidden Markov Model (HMM) method with normalized 
counts in NextGENe software. For dispersion and HMM 
method, one sample file and another control file were 
required. We used a CNV-negative sample, confirmed by 
MLPA, as a control. CNV tool calculated the coverage 
ratios for each region, as well as the amount of dispersion 
(noise) for each region. We assigned a minimum 
dispersion value of 0.01 and a minimum region length 
of 60 in our default setting (minimum normalized read 
counts of 100 and estimated sample purity 100%). Using 
the coverage ratio value and the amount of noise in each 
region, copy number state of each region in the sample 
was reported (duplication/normal/deletion).
Accuracy evaluation compared with Sanger 
sequencing and MLPA
All SNVs and small indels identified by NGS were 
compared with the Sanger sequencing results by setting 
Table 4: Within-run and between-run precision performance for variant frequency calling
Sample: variant Within-run Total
Replicates Mean, % SD, % CV, % Replicates
Mean, 
% SD, % CV, %
YMC1: BRCA1, 
c.5496_5506delinsA 
3 45.27 1.03 2.27 5 45.72 1.28 2.79
YMC2: BRCA2, 
c.2798_2799del
3 47.53 0.15 0.32 5 49.44 2.61 5.29
YMC3: BRCA1, 
c.922_924delinsT
3 49.53 1.01 2.04 5 50.40 2.08 4.13
YMC1: 8 heterozygote 
SNVs 3 49.89 1.56 3.12 5 49.64 1.86 3.76
YMC2: 7 heterozygote 
SNVs 3 49.36 1.69 3.42 5 49.69 1.92 3.86
YMC3: 14 heterozygote 
SNVs 3 50.09 1.50 3.00 5 50.06 1.79 3.57
YMC = Yonsei Medical Center; SD = standard deviation; CV = coefficient of variation. 
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the ROI to ± 20 bp of the exon/intron boundaries in each 
coding exon. The entire length of the ROI of BRCA1 was 
6,450 bp and that of BRCA2 was 11,271 bp. The sensitivity 
of NGS was calculated as the number of true-positive NGS 
calls divided by the number of all sequence variants detected 
by Sanger sequencing. The specificity was calculated as the 
number of true-negative (wild-type) NGS calls divided by the 
number of wild-type bases by Sanger sequencing. The false-
positive rate was calculated as the number of false-positive 
NGS calls divided by the number of false-positive plus the 
number of true-positive calls. The accuracy was calculated 
as the number of true-positive calls plus the number of true-
negative calls divided by all NGS calls. Results from CNV 
analysis were compared with MLPA results. 
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